Drug Profile
PAT SM6
Alternative Names: PAT-SM6; SM-6Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator OncoMab GmbH
- Developer Patrys
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; LDL lipoprotein modulators; Molecular chaperone GRP78 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
- No development reported Malignant melanoma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Malignant-melanoma in Australia (IV, Infusion)
- 22 Sep 2015 PAT SM6 is still in phase-I/II development for Multiple myeloma in Germany
- 18 Feb 2015 Patrys has patent protection for PAT SM6 in Europe